| Expression pattern: |
DN |
| Associated gene: |
AGO2, DAPK1 mRNA, DAPK1 |
| Associated microRNA: |
miR-632 |
| Biological function: |
Suppresses GC cell proliferation, migration and invasion, promotes apoptosis, and reduces xenograft tumor growth. |
| Molecular mechanism: |
circ1811 functions as a ceRNA by sponging miR-632 to upregulate DAPK1 expression. |
| Biological pathway or process: |
ceRNA regulation (other); proliferation (inhibits); migration (inhibits); invasion (inhibits); apoptosis (promotes); metastasis (inhibits) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; Microarray; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
Low circ1811 expression is negatively correlated with lymphatic metastasis; circ1811 shows potential as a biomarker and therapeutic target for GC, with ROC AUC 0.6729. |
| Description: |
circ1811 is a human STAU2-derived circRNA that is down-regulated in gastric cancer tissues. It acts as a tumor suppressor by inhibiting proliferation, migration and invasion, promoting apoptosis, and reducing xenograft tumor growth. Mechanistically, circ1811 sponges miR-632 to relieve repression of DAPK1 mRNA, forming the circ1811/miR-632/DAPK1 axis, and its low expression is associated with lymphatic metastasis and potential diagnostic/therapeutic value. |
| Confidence score: |
0.879 |